Non-pegylated liposomal doxorubicin
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Non-pegylated liposomal doxorubicin, covering 2014-05-13 to 2022-01-18. Get the full timeline:
Most recent: Clinical Trial Update: T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer [Phase 1]